JP2012524278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524278A5 JP2012524278A5 JP2012506186A JP2012506186A JP2012524278A5 JP 2012524278 A5 JP2012524278 A5 JP 2012524278A5 JP 2012506186 A JP2012506186 A JP 2012506186A JP 2012506186 A JP2012506186 A JP 2012506186A JP 2012524278 A5 JP2012524278 A5 JP 2012524278A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- histone
- h3k18ac
- low
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16921209P | 2009-04-14 | 2009-04-14 | |
| US16921609P | 2009-04-14 | 2009-04-14 | |
| US61/169,216 | 2009-04-14 | ||
| US61/169,212 | 2009-04-14 | ||
| US22516209P | 2009-07-13 | 2009-07-13 | |
| US61/225,162 | 2009-07-13 | ||
| PCT/US2010/031112 WO2010120942A2 (en) | 2009-04-14 | 2010-04-14 | Histone modification patterns for clinical diagnosis and prognosis of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012524278A JP2012524278A (ja) | 2012-10-11 |
| JP2012524278A5 true JP2012524278A5 (enExample) | 2013-06-13 |
Family
ID=42983132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506186A Pending JP2012524278A (ja) | 2009-04-14 | 2010-04-14 | がんの臨床診断および予後診断のためのヒストン修飾パターン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120094949A1 (enExample) |
| EP (1) | EP2419737A4 (enExample) |
| JP (1) | JP2012524278A (enExample) |
| CN (1) | CN102460173A (enExample) |
| AU (1) | AU2010236415A1 (enExample) |
| BR (1) | BRPI1013546A2 (enExample) |
| CA (1) | CA2758933A1 (enExample) |
| WO (1) | WO2010120942A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| AU2012349855B2 (en) * | 2011-12-07 | 2017-12-07 | Belgian Volition Sprl | Method for detecting nucleosome adducts |
| GB201303576D0 (en) * | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for predicting therapy efficacy using nucleosome structure biomarkers |
| GB201303575D0 (en) * | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for detecting histone modifications in nucleosomes |
| JP6553085B2 (ja) * | 2013-12-30 | 2019-07-31 | エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ | 消化管癌においてバイオマーカーを測定する方法 |
| JP2016044993A (ja) * | 2014-08-20 | 2016-04-04 | 有限会社マイテック | ヒストン化学修飾判定による癌診断方法 |
| WO2016067029A1 (en) * | 2014-10-29 | 2016-05-06 | Singapore Volition Pte Limited | Method for the enrichment of circulating tumor dna |
| US10639349B2 (en) | 2015-04-06 | 2020-05-05 | The Johns Hopkins University | H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells |
| US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| CA3000858C (en) * | 2015-10-06 | 2022-09-27 | Ontario Institute For Cancer Research (Oicr) | Targeting the histone pathway to detect and overcome anthracyclin resistance |
| GB201612815D0 (en) * | 2016-07-25 | 2016-09-07 | Belgian Volition Sa | Novel combination test |
| JP7104689B2 (ja) * | 2016-08-09 | 2022-07-21 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有害事象を示すマーカーとしてのヒストンおよび／またはｐｒｏＡＤＭ |
| CN108957004B (zh) * | 2018-07-09 | 2021-10-19 | 东南大学 | 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用 |
| CN110221072B (zh) * | 2019-06-10 | 2022-08-02 | 东南大学 | 检测H3K9甲基化和E-cadherin表达量试剂在制备肝癌预后评估试剂盒的应用 |
| CN112904006B (zh) * | 2021-01-28 | 2022-12-27 | 中山大学 | 一种乳腺癌预后预测分子标志物及其应用 |
| WO2024077601A1 (en) * | 2022-10-14 | 2024-04-18 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Peptide vaccines against glioma and uses thereof |
| WO2024233383A1 (en) * | 2023-05-05 | 2024-11-14 | University Of Utah Research Foundation | Systems and methods for point-of-care assessment based on pathology image analysis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| DE602006018458D1 (de) * | 2005-04-29 | 2011-01-05 | Univ California | Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose |
| WO2007015947A2 (en) * | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies |
-
2010
- 2010-04-14 WO PCT/US2010/031112 patent/WO2010120942A2/en not_active Ceased
- 2010-04-14 BR BRPI1013546-4A patent/BRPI1013546A2/pt not_active IP Right Cessation
- 2010-04-14 AU AU2010236415A patent/AU2010236415A1/en not_active Abandoned
- 2010-04-14 CA CA2758933A patent/CA2758933A1/en not_active Abandoned
- 2010-04-14 JP JP2012506186A patent/JP2012524278A/ja active Pending
- 2010-04-14 EP EP10765132A patent/EP2419737A4/en not_active Withdrawn
- 2010-04-14 CN CN2010800251368A patent/CN102460173A/zh active Pending
- 2010-04-14 US US13/262,219 patent/US20120094949A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524278A5 (enExample) | ||
| Zhou et al. | Increased expression of long-noncoding RNA ZFAS1 is associated with epithelial-mesenchymal transition of gastric cancer | |
| Khan et al. | Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer | |
| Chen et al. | Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma | |
| Maráz et al. | Thrombocytosis has a negative prognostic value in lung cancer | |
| Wang et al. | Lymphatic microvessel density and vascular endothelial growth factor-C and-D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature | |
| Carr et al. | Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro | |
| Ding et al. | HOXB8 promotes tumor metastasis and the epithelial–mesenchymal transition via ZEB2 targets in gastric cancer | |
| Lu et al. | Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival | |
| Zhang et al. | The prognostic value of the preoperative albumin to alkaline phosphatase ratio in patients with non‐small cell lung cancer after surgery | |
| US20180051344A1 (en) | Embryonic isoforms of gata6 and nkx2-1 for use in lung cancer diagnosis | |
| Dabner et al. | Merkel cell Polyomavirus and p63 status in Merkel cell carcinoma by immunohistocnemistry: Merkel cell Polyomavirus positivity is inversely correlated with sun damage, but neither is correlated with outcome | |
| Hu et al. | Noninvasive diagnosis of nasopharyngeal carcinoma based on phenotypic profiling of viral and tumor markers on plasma extracellular vesicles | |
| Ge et al. | Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma | |
| Kuiper et al. | VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib | |
| Fiala et al. | High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib | |
| Martí et al. | Prognostic value of serum neutrophil gelatinase‐associated lipocalin in metastatic and nonmetastatic colorectal cancer | |
| Munoz-Colmenero et al. | Plasma tumor M2-pyruvate kinase levels in different cancer types | |
| Jouhi et al. | The expression of Toll-like receptors 2, 4, 5, 7 and 9 in Merkel cell carcinoma | |
| Alexander et al. | KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas | |
| JP2017505897A5 (enExample) | ||
| Zhao et al. | Quantitative proteomic analysis of optimal cutting temperature (OCT) embedded core-needle biopsy of lung cancer | |
| Marín-Rubio et al. | S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma | |
| Ellinger et al. | Evaluation of global histone acetylation levels in bladder cancer patients | |
| Jessica Mok et al. | Is C-reactive protein the single most useful predictor of difficult laparoscopic cholecystectomy or its conversion? A pilot study |